Last reviewed 2026-04-23 · How we verify

JS002

JS002 is a monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2) to enhance anti-tumor immune responses.

JS002 is a monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2) to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Hepatocellular carcinoma, Gastric cancer.

At a glance

Mechanism of action

JS002 binds to programmed death receptor 1 (PD-1) on T cells, preventing engagement with PD-L1 and PD-L2 expressed on tumor cells and immune cells. This blockade reverses T cell exhaustion and restores anti-tumor immunity, allowing the immune system to recognize and eliminate cancer cells more effectively.

Approved indications

• Non-small cell lung cancer
• Hepatocellular carcinoma
• Gastric cancer

Common side effects

• Fatigue
• Decreased appetite
• Immune-related adverse events (pneumonitis, hepatitis, colitis)
• Infusion-related reactions

Key clinical trials

• Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia (PHASE3)
• A Pharmacokinetic Study of JS002 in Healthy Subjects (PHASE1)
• To Evaluate the Efficacy and Safety of JS002 in HoFH Patients (PHASE2)
• A Study Explore JS001+JS002 in Patients With Advanced Cancer (PHASE1)
• A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH). (PHASE3)
• The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia (PHASE3)
• The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia (PHASE3)
• A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia.. (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.